Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Medulloblastoma 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Diseases 1Glioma 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × sonidegib × Clear all
NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Novartis

Phase 1/2 Completed
76 enrolled 18 charts
CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡